
Product News
XenoTech Adds In Vitro Toxicology to Its Drug Development Services

Product News
XenoTech Adds In Vitro Toxicology to Its Drug Development Services
Want a FREE PDF version of This Product News?
Complete the form below and we will email you a PDF version of "XenoTech Adds In Vitro Toxicology to Its Drug Development Services"
First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?
The company is launching the ECVAM validated skin irritation screening assay (OECD TG 439) immediately, with additional screens for skin sensitization, ocular irritation and other organotypic models beginning this fall (2015) and future platforms expanding into endocrine disruption, genetox and hepatotoxicity.

“The formation of our new in vitro toxicology department shows XenoTech’s commitment to expanding into complementing areas around our extensive ADME - DMPK expertise to better predict in vivo outcomes through in vitro systems,” said XenoTech COO Jason Neat.
Advertisement